Skip to Content
MilliporeSigma
All Photos(1)

Documents

T2807

Sigma-Aldrich

Thymidine Phosphorylase, recombinant from Escherichia coli

recombinant, expressed in E. coli, buffered aqueous solution, ≥500 units/mL

Sign Into View Organizational & Contract Pricing

Synonym(s):
Thymidine:orthophosphate deoxy-D-ribosyltransferase
CAS Number:
Enzyme Commission number:
MDL number:
UNSPSC Code:
12352204
NACRES:
NA.54

recombinant

expressed in E. coli

Quality Level

form

buffered aqueous solution

concentration

≥500 units/mL

UniProt accession no.

storage temp.

2-8°C

Gene Information

Escherichia coli K12 ... deoA(948901)

Looking for similar products? Visit Product Comparison Guide

General description

Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation.

Application

Thymidine phosphorylase has been used in a study to assess TAS-102 treatment in patients with advanced solid tumors. Thymidine phosphorylase has also been used in a study to investigate antitumor effects of the FP3 protein on patient-derived tumor tissue xenograft models of primary colon carcinoma.

Biochem/physiol Actions

An enzyme that catalyzes the reversible conversion of thymidine to thymine. Thymidine phosphorylase is part of the pyrimidine nucleoside salvage pathway. This pathway allows pyrimidine bases to be recycled for nucleotide biosynthesis, while the pentose 1-phosphates are converted to intermediates of the pentose phosphate shunt and glycolysis. The E. coli thymidine phosphorylase shares 40% sequence homology with the human sequence, which has been found to be identical to the angiogenic agent platelet-derived endothelial growth factor. The purified E. coli enzyme has been shown to stimulate blood vessel growth in chick chorioallantoic membrane assays.

Unit Definition

One unit will convert 1.0 μmole each of thymidine and phosphate to thymine and 2-deoxyribose 1-phosphate per min at pH 7.4 at 25°C.

Physical form

Solution in 0.5 M potassium phosphate containing 2 mM uracil, 0.02% sodium azide and bovine serum albumin

Preparation Note

Cloned from E. coli and produced in overexpressing E. coli

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Charlotte Gasson et al.
Journal of pharmaceutical and biomedical analysis, 72, 16-24 (2012-11-14)
Erythrocyte encapsulated thymidine phosphorylase (EE-TP) is under development as an enzyme replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a fatal metabolic disorder resulting from an inherited deficiency of the enzyme thymidine phosphorylase. We report here the development and validation of
Jian Zhang et al.
Cancer chemotherapy and pharmacology, 71(1), 103-113 (2012-10-12)
The difference between combinational and pre-planned sequential therapies using regimens that include non-anthracycline and taxane in the first-line setting remains unclear. The purpose of this study is to explore the interaction between vinorelbine (N) and capecitabine (X) in breast cancer
Domenico Ribatti et al.
Expert opinion on therapeutic targets, 16(12), 1215-1225 (2012-09-18)
Several anti-angiogenic agents have been developed and some of them have been clinically applied in the tumor therapy. Anti-angiogenic therapy faces some hurdles: inherent or acquired resistance, increased invasiveness, and lack of biomarkers. Characterization of tumor endothelial markers may help
T Doi et al.
British journal of cancer, 107(3), 429-434 (2012-06-28)
TAS-102 consists of α, α, α-trifluorothymidine (TFT) and an inhibitor of thymidine phosphorylase (TPI). We conducted a dose-escalation phase I study in Japanese patients with advanced solid tumours. TAS-102 was administered twice daily on days 1-5 and days 8-12 in
Michelle Levene et al.
Toxicological sciences : an official journal of the Society of Toxicology, 131(1), 311-324 (2012-09-15)
Erythrocyte-encapsulated thymidine phosphorylase (EE-TP) is currently under development as an enzyme replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), an autosomal recessive disorder caused by a deficiency of thymidine phosphorylase. The rationale for the development of EE-TP is based on the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service